Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
Amneal Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Amneal Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $175.57M, down 13.7% year over year. For fiscal 2025 it was $186.18M, down 2.4% from the year before. The highest annual figure on record is $201.85M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.18M | -2.4% |
| FY2024 | Dec 31, 2024 | $190.71M | +16.3% |
| FY2023 | Dec 31, 2023 | $163.95M | -16.2% |
| FY2022 | Dec 31, 2022 | $195.69M | -3.1% |
| FY2021 | Dec 31, 2021 | $201.85M | +12.2% |
| FY2020 | Dec 31, 2020 | $179.93M | -4.3% |
| FY2019 | Dec 31, 2019 | $188.05M | -3.2% |
| FY2018 | Dec 31, 2018 | $194.19M | +13.3% |
| FY2017 | Dec 31, 2017 | $171.42M | -4.2% |
| FY2016 | Dec 31, 2016 | $179.02M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $39.02M | -18.7% |
| Q1 FY2026 | Mar 31, 2026 | $38.38M | -4.1% |
| Q4 FY2025 | Dec 31, 2025 | $34.82M | -35.8% |
| Q3 FY2025 | Sep 30, 2025 | $63.35M | +3.7% |
| Q2 FY2025 | Jun 30, 2025 | $47.96M | +33.0% |
| Q1 FY2025 | Mar 31, 2025 | $40.04M | +1.9% |
| Q4 FY2024 | Dec 31, 2024 | $54.27M | +17.7% |
| Q3 FY2024 | Sep 30, 2024 | $61.10M | +47.7% |
| Q2 FY2024 | Jun 30, 2024 | $36.05M | -4.6% |
| Q1 FY2024 | Mar 31, 2024 | $39.30M | +1.6% |
| Q4 FY2023 | Dec 31, 2023 | $46.09M | +10.0% |
| Q3 FY2023 | Sep 30, 2023 | $41.38M | -17.6% |
| Q2 FY2023 | Jun 30, 2023 | $37.80M | -25.5% |
| Q1 FY2023 | Mar 31, 2023 | $38.69M | -26.7% |
| Q4 FY2022 | Dec 31, 2022 | $41.91M | -19.2% |
| Q3 FY2022 | Sep 30, 2022 | $50.24M | +2.7% |
| Q2 FY2022 | Jun 30, 2022 | $50.75M | -4.0% |
| Q1 FY2022 | Mar 31, 2022 | $52.80M | +9.6% |
| Q4 FY2021 | Dec 31, 2021 | $51.87M | -3.0% |
| Q3 FY2021 | Sep 30, 2021 | $48.93M | +9.9% |
| Q2 FY2021 | Jun 30, 2021 | $52.86M | +16.0% |
| Q1 FY2021 | Mar 31, 2021 | $48.18M | +32.4% |
| Q4 FY2020 | Dec 31, 2020 | $53.46M | +11.3% |
| Q3 FY2020 | Sep 30, 2020 | $44.52M | +16.8% |
| Q2 FY2020 | Jun 30, 2020 | $45.57M | -5.1% |
| Q1 FY2020 | Mar 31, 2020 | $36.38M | -32.5% |
| Q4 FY2019 | Dec 31, 2019 | $48.05M | -16.1% |
| Q3 FY2019 | Sep 30, 2019 | $38.13M | -10.0% |
| Q2 FY2019 | Jun 30, 2019 | $48.02M | -4.6% |
| Q1 FY2019 | Mar 31, 2019 | $53.86M | +21.8% |
| Q4 FY2018 | Dec 31, 2018 | $57.30M | +31.7% |
| Q3 FY2018 | Sep 30, 2018 | $42.35M | +2.5% |
| Q2 FY2018 | Jun 30, 2018 | $50.34M | +6.7% |
| Q1 FY2018 | Mar 31, 2018 | $44.21M | – |
| Q4 FY2017 | Dec 31, 2017 | $43.49M | – |
| Q3 FY2017 | Sep 30, 2017 | $41.32M | – |
| Q2 FY2017 | Jun 30, 2017 | $47.18M | – |
See a number that looks wrong?